Logo

VACH

Voyager Acquisition Corp.

VACH

Voyager Acquisition Corp. • NASDAQ
$10.51 ▲ 0.00% (+0.00)
Market Cap $332.38 M
52w High $10.99
52w Low $10.01
Dividend Yield 0%
P/E 35.03
Volume 4.64K
Outstanding Shares 31.63M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $405.805K ▲ $2.359M ▼ 0% $0.093 ▲ $0 ▲
Q2-2025 $0 $240.935K ▼ $2.492M ▲ 0% $0.079 ▼ $-240.935K ▲
Q1-2025 $0 $265.009K ▲ $2.433M ▼ 0% $0.096 ▲ $-265.009K ▼
Q4-2024 $0 $70.877K ▼ $2.923M ▲ 0% $0.092 ▲ $-70.877K ▲
Q3-2024 $0 $529.234K $1.322M 0% $0.067 $-529.234K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $252.35K ▲ $267.548M ▲ $12.536M ▲ $-12.272M ▼
Q2-2025 $92.494K ▼ $264.824M ▲ $12.171M ▲ $252.653M ▲
Q1-2025 $445.492K ▼ $262.292M ▲ $12.131M ▲ $250.161M ▲
Q4-2024 $668.285K ▼ $259.812M ▲ $12.084M ▲ $247.728M ▲
Q3-2024 $757.895K $256.881M $12.075M $244.806M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $2.359M ▼ $159.856K ▲ $0 $0 $159.856K ▲ $159.856K ▲
Q2-2025 $2.492M ▲ $-352.998K ▼ $0 $0 $-352.998K ▼ $-352.998K ▼
Q1-2025 $2.433M ▼ $-222.793K ▼ $0 ▲ $0 $-222.793K ▼ $-222.793K ▼
Q4-2024 $2.923M ▲ $-89.609K ▲ $-254.265M $0 ▼ $-89.61K ▼ $-89.609K ▲
Q3-2024 $1.322M $-613.859K $-254.265M $255.612M $732.895K $-613.859K

Five-Year Company Overview

Income Statement

Income Statement Voyager Acquisition Corp. is essentially a blank‑check company right now, so its income statement is not a typical operating business. It has no meaningful revenue and no real operating activity. Any earnings per share you see are mostly the byproduct of its SPAC structure and interest on cash, not from selling products or services. Until the merger with VERAXA closes, the income statement mainly reflects administrative costs and SPAC mechanics rather than underlying business performance.

Balance Sheet

Balance Sheet The balance sheet is very light, which is normal for a newly listed SPAC. It shows a small base of assets and equity and no traditional operating debt, because the real cash pool usually sits in a trust account dedicated to completing a deal. In other words, the current balance sheet tells you more about the SPAC structure than about business strength. After the merger, the balance sheet will effectively transform into that of VERAXA, with very different assets, funding needs, and risk profile typical of a clinical‑stage biotech.

Cash Flow

Cash Flow Cash flows are essentially flat at this stage. There is no meaningful operating cash inflow because there is no operating business yet, and there is no real investment in physical assets either. Cash movements mainly relate to SPAC setup and listing, not to growth spending. The important cash dynamic comes later: if the transaction with VERAXA closes, a sizeable pool of cash could become available to fund drug development, but that will depend on redemptions and deal terms at closing.

Competitive Edge

Competitive Edge As a shell company, Voyager itself does not have a competitive position in the traditional sense—its role is to provide a path to the public markets and capital. The more relevant competitive picture is that of VERAXA, the planned merger partner. VERAXA would be entering a very crowded and fast‑moving oncology field but with some differentiated technology, strong scientific roots, and strategic partnerships. That combination can offer an edge, but it also means competing against much larger and better‑funded pharma and biotech players, with all the usual clinical and regulatory uncertainties of cancer drug development.

Innovation and R&D

Innovation and R&D The real innovation story sits with VERAXA rather than Voyager. VERAXA’s platform focuses on next‑generation antibody‑based cancer treatments designed to hit tumors more precisely while sparing healthy tissue. Its BiTAC technology, genetic code expansion tools, and microfluidic plus AI‑driven discovery engine are aimed at creating more selective, more stable, and potentially safer antibody‑drug conjugates and T‑cell engagers. A lead program in blood cancer and a broader early pipeline across several solid tumors show an R&D‑heavy profile: high scientific ambition and long development timelines, with outcomes that are inherently uncertain but could be meaningful if the data continue to be positive.

Summary

VACH today is best viewed as a financial vehicle in transition, not an operating company. Its current financial statements are thin and mostly reflect the mechanics of a SPAC rather than business fundamentals. The real story for the future is the proposed combination with VERAXA Biotech, which would turn VACH into an early‑stage oncology biotech with advanced, but still largely unproven, technology platforms and drug candidates. That shift brings substantial scientific and execution upside potential, paired with the typical risks of drug development, regulatory approval, competition in cancer therapeutics, and the need for ongoing funding. Anyone reviewing VACH should recognize that they are effectively assessing an upcoming biotech story rather than the shell company’s current financial performance.

NEWS

October 21, 2025 · 5:30 PM UTC

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRTAF, LCTC, VACH, and EFIN

Read more

September 30, 2025 · 8:00 AM UTC

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

Read more